Thiazolidinedione (TZD) is a class of oral antidiabetic drug that improves insulin resistance by acting as an agonist to the nuclear hormone receptor of peroxisome proliferator-activated receptors gamma (PPARγ) [26,27,28], and PPARγ activation may affect the risk of cancer [29,30]. This evidence concerns the gene PPARG and Insulin resistance.